AU2002364501A1 - Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer - Google Patents
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancerInfo
- Publication number
- AU2002364501A1 AU2002364501A1 AU2002364501A AU2002364501A AU2002364501A1 AU 2002364501 A1 AU2002364501 A1 AU 2002364501A1 AU 2002364501 A AU2002364501 A AU 2002364501A AU 2002364501 A AU2002364501 A AU 2002364501A AU 2002364501 A1 AU2002364501 A1 AU 2002364501A1
- Authority
- AU
- Australia
- Prior art keywords
- diagnosis
- therapy
- compositions
- methods
- human cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2002/027836 WO2003022991A2 (fr) | 2001-09-07 | 2002-08-30 | Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires |
AU2002323543 | 2002-08-30 | ||
PCT/US2002/034987 WO2004020999A1 (fr) | 2002-08-30 | 2002-10-30 | Compositions et procedes d'utilisation de peptides de ciblage conçus pour le diagnostic et le traitement du cancer humain |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002364501A1 true AU2002364501A1 (en) | 2004-03-19 |
Family
ID=31975571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002364501A Abandoned AU2002364501A1 (en) | 2002-08-30 | 2002-10-30 | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1546714A4 (fr) |
AU (1) | AU2002364501A1 (fr) |
CA (1) | CA2496938A1 (fr) |
WO (1) | WO2004020999A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322559A3 (fr) | 2002-07-04 | 2011-08-03 | Patrys Limited | Anticorps specifiques de neoplasme et utilisations associees |
DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
EP1531162A1 (fr) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations |
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
WO2005065418A2 (fr) * | 2003-12-31 | 2005-07-21 | Board Of Regents, The University Of Texas System | Compositions et procedes d'utilisation de peptides de ciblage pour le diagnostic et la therapie |
JP5479087B2 (ja) * | 2006-04-07 | 2014-04-23 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | アデノ随伴ウイルスファージ粒子に関する方法および組成物 |
JP5374360B2 (ja) | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | 抗grp78抗体を有効成分として含む医薬組成物 |
WO2009155556A2 (fr) * | 2008-06-20 | 2009-12-23 | The Board Of Regents Of The University Of Texas System | Peptides de ciblage de crkl |
CN102120755B (zh) * | 2010-04-23 | 2013-04-03 | 江苏省人民医院 | 一种棕色脂肪组织靶向性多肽及其应用 |
CN113278731A (zh) * | 2021-05-12 | 2021-08-20 | 广西医科大学 | 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) * | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6093800A (en) * | 1996-09-06 | 2000-07-25 | The Regents Of The University Of California | E25a protein, methods for production and use thereof |
US6261789B1 (en) * | 1997-03-10 | 2001-07-17 | The Regents Of The University Of California | Methods for detecting the presence of a PSCA protein using PSCA antibodies |
US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
AU2001290652A1 (en) * | 2000-09-08 | 2002-03-22 | Board Of Regents, The University Of Texas System | Methods and compositions for in vitro targeting |
CA2421271A1 (fr) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Peptides de ciblage humains et murins identifies par expression phagique |
-
2002
- 2002-10-30 AU AU2002364501A patent/AU2002364501A1/en not_active Abandoned
- 2002-10-30 CA CA002496938A patent/CA2496938A1/fr not_active Abandoned
- 2002-10-30 WO PCT/US2002/034987 patent/WO2004020999A1/fr not_active Application Discontinuation
- 2002-10-30 EP EP02799873A patent/EP1546714A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2496938A1 (fr) | 2004-03-11 |
EP1546714A1 (fr) | 2005-06-29 |
WO2004020999A1 (fr) | 2004-03-11 |
EP1546714A4 (fr) | 2007-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003302892A1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
WO2004030615A8 (fr) | Compositions et procedes de diagnostic et de traitement de tumeur | |
EP1571968A3 (fr) | Compositions et methodes permettant de diagnostiquer et de traiter une tumeur | |
WO2004016225A8 (fr) | Compositions et methodes de diagnostic et de traitement des tumeurs | |
WO2004045516A9 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
EP1572091A3 (fr) | Compositions et methodes de diagnostic et de traitement de tumeurs | |
AU2002251844A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
WO2004060270A8 (fr) | Compositions et methodes pour diagnostiquer et traiter des tumeurs | |
WO2003057160A8 (fr) | Compositions et methodes de diagnostic et de traitement d'une tumeur | |
AU2002311909A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
AU2001252945A1 (en) | Compositions and methods for therapy and diagnosis of colon cancer | |
AU2002303219A1 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
AU2002359330A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2005003154A8 (fr) | Compositions et methodes de diagnostic et de traitement de tumeur | |
AU2002364501A1 (en) | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer | |
AU2002313726A1 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
EP1532162A4 (fr) | Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme | |
AU2003237792A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU2003246592A1 (en) | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases | |
AU2003245927A1 (en) | Target genes for the diagnosis and treatment of cancer | |
AU2003230849A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
AU2003250912A1 (en) | Agents and methods for diagnosis and therapy of cancer and cancer risk assessment | |
AU2003260301A1 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
AU2002253899A1 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
AU2003245858A1 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |